Bellerophon Therapeutics (Bellerophon Therapeutics) Total Receivables : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Bellerophon Therapeutics Total Receivables?

Bellerophon Therapeutics's Total Receivables for the quarter that ended in Sep. 2023 was $0.00 Mil.

Bellerophon Therapeutics Total Receivables Historical Data

The historical data trend for Bellerophon Therapeutics's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellerophon Therapeutics Total Receivables Chart

Bellerophon Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Receivables

Get a 7-Day Free Trial

Bellerophon Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Bellerophon Therapeutics Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Bellerophon Therapeutics Total Receivables Related Terms

Thank you for viewing the detailed overview of Bellerophon Therapeutics's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Bellerophon Therapeutics (Bellerophon Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellerophon Therapeutics Inc (OTCPK:BLPH) » Definitions » Total Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

184 Liberty Corner Road, Suite 302, Warren, NJ, USA, 07059

Website

https://www.bellerophon.com

Bellerophon Therapeutics Inc is a clinical-stage therapeutics company. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. The company's products are aimed at the treatment of different kinds of pulmonary hypertension.

Executives

Puissance Life Science Opportunities Fund Vi	10 percent owner	950 THIRD AVENUE, FL 25, NEW YORK NY 10022
Naseem Amin	director	53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Mary Ann Cloyd	director	184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Theodore T Wang	director	C/O PUISSANCE CAPITAL MANAGEMENT LP, 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Scott P Bruder	director	C/O BELLEROPHON THERAPEUTICS, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Crispin Teufel	director	184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Puissance Capital Fund (gp) Llc	10 percent owner	950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Parag Suresh Shah	officer: VP of Business Operations	C/O BELLEROPHON THERAPEUTICS, INC., 184 LIBERTY CORNER ROAD, SUITE 302, NEW JERSEY NJ 07059
Martin Dekker	officer: See Remarks	53 FRONTAGE ROAD, SUITE 301, PERRYVILLE III CORPORATE PARK, HAMPTON NJ 08827
Peter Fernandes	officer: See Remarks	PERRYVILLE III CORPORATE PARK, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Bobae Kim	officer: VP Reg. Affairs & Quality	184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Nicholas Laccona	officer: Controller, (PFO & PAO)	184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Steven B Klinsky	10 percent owner	C/O NEW MOUNTAIN CAPITAL, L.L.C., 1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019
New Mountain Capital, L.l.c.	10 percent owner	1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019
New Mountain Investments Ii, Llc	10 percent owner	787 SEVENTH AVENUE, 49TH FLOOR, NEW YORK NY 10019